药明康德第三季营收超百亿 在手订单再创历史新高

Core Viewpoint - WuXi AppTec (药明康德) reported steady revenue and profit growth in Q3, despite uncertainties in the industry due to proposed U.S. biosafety laws [1][2] Financial Performance - The company achieved a total revenue of 277.02 billion yuan in the first three quarters, with Q3 revenue reaching 104.61 billion yuan, a year-on-year increase of 14.6% after excluding commercial projects [1] - The net profit attributable to shareholders for the first three quarters was 65.33 billion yuan, with an adjusted non-IFRS net profit of 73.64 billion yuan [1] - Free cash flow for the first three quarters reached 55.6 billion yuan, showing a 10.4% year-on-year growth after excluding COVID-19 commercial projects [1] Order Backlog and Client Base - The company's order backlog reached a record high of 438.2 billion yuan by the end of Q3, indicating sustained demand for WuXi AppTec's services despite external uncertainties [1] - The company maintained a large active client base of over 6,000, adding more than 800 new clients in the first three quarters [1] Revenue by Region - Revenue from the U.S. market was 176.2 billion yuan, with a year-on-year growth of 7.6% after excluding COVID-19 commercial projects [2] - Revenue from Europe reached 35.3 billion yuan, showing a year-on-year increase of 14.8% [2] - Revenue from China was 51.6 billion yuan, reflecting a year-on-year decline of 3.9% [2] - Revenue from Japan and other countries was 14 billion yuan, with a year-on-year decline of 16.5% [2] Business Segments - The chemical business segment (WuXi Chemistry) returned to positive year-on-year growth in Q3 after four quarters of decline, with a 26.4% increase after excluding COVID-19 commercial projects [2] - The TIDES business (oligonucleotides and peptides), driven by GLP-1 drugs, reported a revenue of 35.5 billion yuan in the first three quarters, representing a strong year-on-year growth of 71% [2] Future Outlook - The company expects to meet its annual targets, projecting total revenue between 383 billion and 405 billion yuan, free cash flow of 60 billion to 70 billion yuan, and adjusted non-IFRS net profit margins to remain consistent with the previous year [3] - Q4 revenue is anticipated to continue its growth trend [3]